Stockscreener 앱 받기
12.02
0.91%
-0.11
시간 외 거래:
12.15
0.13
+1.08%
전일 마감가:
$12.13
열려 있는:
$12.104
하루 거래량:
985.82K
Relative Volume:
1.12
시가총액:
$657.25M
수익:
$27.46M
순이익/손실:
$-46.05M
주가수익비율:
-9.3178
EPS:
-1.29
순현금흐름:
$-33.83M
1주 성능:
+8.19%
1개월 성능:
+4.07%
6개월 성능:
+54.70%
1년 성능:
+62.65%
1일 변동 폭
$11.57
$12.22
1주일 범위
$10.90
$12.24
52주 변동 폭
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(321) 939-3416
주소
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
ZVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
12.02 | 627.72M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-02 | 개시 | H.C. Wainwright | Buy |
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Zevra ZVRA 2025Q2 Earnings Preview Potential Upside on Data-Driven Regulatory Strategy - AInvest
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing' - Yahoo Finance
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference | ZVRA Stock News - GuruFocus
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Rare Disease Innovator Zevra Therapeutics Sets Key Investor Presentation at Major Growth Conference - Stock Titan
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - GlobeNewswire
Zevra Therapeutics to report Q2 2025 results on Aug 12. - AInvest
Quant Funds Rotate Into Zevra Therapeutics Inc. StockStock Screener With Smart Filters Highlights Top Picks - metal.it
What are the latest earnings results for Zevra Therapeutics Inc.Extraordinary market timing - Jammu Links News
Zevra Therapeutics Inc. Stock Analysis and ForecastExponential return rates - Jammu Links News
What catalysts could drive Zevra Therapeutics Inc. stock higher in 2025Unlock powerful trading signals and alerts - Jammu Links News
What is Zevra Therapeutics Inc. company’s growth strategyDiscover top stock picks for aggressive growth - Jammu Links News
What is the risk reward ratio of investing in Zevra Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
What are analysts’ price targets for Zevra Therapeutics Inc. in the next 12 monthsUnlock hidden market opportunities today - Jammu Links News
Should I hold or sell Zevra Therapeutics Inc. stock in 2025Free Investment Community - Jammu Links News
How many analysts rate Zevra Therapeutics Inc. as a “Buy”Outstanding capital growth - Jammu Links News
Does Zevra Therapeutics Inc. stock perform well during market downturnsFree Market Volatility Navigation Tips - Jammu Links News
Is Zevra Therapeutics Inc. stock overvalued or undervaluedCapitalize on market trends with confidence - Jammu Links News
Is Zevra Therapeutics Inc. a growth stock or a value stockGet daily updates on promising stocks - Jammu Links News
How strong is Zevra Therapeutics Inc. company’s balance sheetFree Stock Selection - jammulinksnews.com
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect? - sharewise.com
Applying Elliott Wave Theory to Zevra Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it
How Zevra Therapeutics Inc. stock performs during market volatilitySecure Capital Picks With Upside Potential Tracked - metal.it
Despite currently being unprofitable, Zevra Therapeutics (NASDAQ:ZVRA) has delivered a 102% return to shareholders over 3 years - simplywall.st
What institutional investors are buying Zevra Therapeutics Inc. stockMarket Forecast Alerts For Smart Trading - Jammu Links News
Zevra Therapeutics' Strategic Expansion into the European Market with Arimoclomol for NPC: A Deep Dive into Regulatory, Commercial, and Market Access Potential - AInvest
Zevra Therapeutics Submits Marketing Authorization Application t - GuruFocus
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C | ZVRA Stock News - GuruFocus
ZVRA: Zevra Therapeutics Seeks EMA Approval for NPC Drug Arimoclomol - GuruFocus
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C - GlobeNewswire
Zevra's Breakthrough NPC Treatment Heads to EMA Review: 270+ Patient Data Shows Promise - Stock Titan
Intrinsic Value of Zevra Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree High-Accuracy Stock Picks - metal.it
Published on: 2025-07-28 03:53:57 - Jammu Links News
Is Zevra Therapeutics Inc. stock overhyped or has real potentialMarket Timing Advice - metal.it
What makes Zevra Therapeutics Inc. stock price move sharplyFree Deep Market Trend Analysis - metal.it
What drives Zevra Therapeutics Inc. stock priceSky-high profits - PrintWeekIndia
What analysts say about Zevra Therapeutics Inc. stockSuperior stock growth - PrintWeekIndia
Is Zevra Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - Jammu Links News
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):